Search for media from: "Kelda Tan"

Media

01:27:36 Round Table Discussion on IMpower150 (Exchange… Round Table Discussion on IMpower150 (Exchange between Thailand, Vietnam and Singapore)	Round Table Discussion on IMpower150 (Exchange between Thailand, Vietnam and Singapore) round table discussion of Impower150, discussing use of T+A in post-tki setting and heavy tumour burden setting. showcase of patient case studies by different doctors impower150 post-tki egfr heavy tumour burden From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No Language (In English) English
09:13 SINGAPORE HCC Patient Video SINGAPORE HCC Patient Video	SINGAPORE HCC Patient Video NCC Chinese Patient on Tecentriq+Avastin hcc toh han chong tecentriq avastin singapore ncc From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years
01:33:13 The Major Breakthroughs in Lung Cancer 2020 The Major Breakthroughs in Lung Cancer 2020	The Major Breakthroughs in Lung Cancer 2020 Breakthroughs in Lung Cancer in 2020 - immunotherapy and targeted therapy tony mok daniel tan amit jain lau yat ming tigit skyscraper cityscape From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years Language (In English) English
01:19:56 Changing Landscape of PD-L1-high NSCLC treatments Changing Landscape of PD-L1-high NSCLC treatments	Changing Landscape of PD-L1-high NSCLC treatments Changing landscape for PD-L1-high NSCLC treatmentsSpeakers: Dr Ross Soo (Singapore, Moderator), Dr Mark Socinski (US, Speaker), Dr Roy Herbst (US, Speaker), Dr Yuh Min Chen (Taiwan,… impower150 impower110 prof. roy herbst socinski ross soo yuh-min chen pd-l1 (sp142) pd-l1 pd-l1-high lung cancer sp142 22c3 From Kelda Tan 0 likes 189 plays 0 Content Declaration Keep for 3 Years Language (In English) English
02:09:00 Global Vision: Immunotherapy in NSCLC (26May2020) Global Vision: Immunotherapy in NSCLC (26May2020)	Global Vision: Immunotherapy in NSCLC (26May2020) Prof Zhou Caicun (Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai), Dr Ross Soo (National University Cancer Institute, Singapore) and a panel of Chinese oncologists were… tecentriq lung nsclc impower150 impower110 zhou caicun ross soo From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years Language (In English) English
01:45:41 Solving the NSCLC Puzzle in the era of cancer… Solving the NSCLC Puzzle in the era of cancer immunotherapy	Solving the NSCLC Puzzle in the era of cancer immunotherapy Agenda 1. Opening - Dr Tho Lye Mun (Malaysia) 2. Update on frontline NSCLC treatment in wake of immunotherapy approvals - Dr Florian Fuchs (Germany) 3. Making sense of it all - CIT strategy in… impower150 immunotherapy lung cancer florian fuchs pongwut danchaivijitr From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years Language (In English) English
01:16:25 Setting The Standards for 1st Line ALK NSCLC… Setting The Standards for 1st Line ALK NSCLC Treatment	Setting The Standards for 1st Line ALK NSCLC Treatment Interactive case-study focused webinar to learn about:• Differences in survival, CNS control and toxicity profiles among current andemerging treatment specifically in the landscape of 1L ALK+… alecensa tanujaa muhammad azrif riyaz shah alexander drilon alectinib nsclc From Kelda Tan 0 likes 0 plays 0 Content Declaration Keep for 3 Years Language (In English) English